for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evoke Pharma Inc

EVOK.OQ

Latest Trade

0.95USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.50

 - 

3.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.95
Open
--
Volume
--
3M AVG Volume
17.13
Today's High
--
Today's Low
--
52 Week High
3.32
52 Week Low
0.50
Shares Out (MIL)
24.11
Market Cap (MIL)
22.79
Forward P/E
-2.70
Dividend (Yield %)
--

Latest Developments

More

Evoke Pharma Completed Manufacturing Commercial Scale Batches Of Product Candidate Gimoti

Evoke Pharma Reports Q2 Loss Per Share $0.09

Evoke Pharma Requests Type A FDA Meeting To Plan For Resubmission Of Gimoti NDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evoke Pharma Inc

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry

Biotechnology & Drugs

Contact Info

420 Stevens Ave Ste 370

+1.858.3451494

https://evokepharma.com/

Executive Leadership

Cam L. Garner

Chairman and Co Founder

David A. Gonyer

CEO, Founder, Director

Matthew J D'Onofrio

Executive Vice President, Chief Business Officer Treasurer, Secretary ,

Marilyn R. Carlson

Chief Medical Officer

Todd C. Brady

Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.150

2017

-0.820

2018

-0.460

2019(E)

-0.350
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-125.73
Return on Equity (TTM)
-103.24

Latest News

BRIEF-Evoke Pharma Posts Loss Of $0.13 Per Share in Q1

* EVOKE PHARMA REPORTS FIRST QUARTER 2018 RESULTS AND HIGHLIGHTS

BRIEF-Evoke Pharma Granted Gender Specific Patent For Gimoti In Mexico

* EVOKE GRANTED GENDER SPECIFIC PATENT FOR GIMOTI™ IN MEXICO Source text for Eikon: Further company coverage:

BRIEF-Evoke Announces Agreement With Mallinckrodt To Amend Milestone Payments

* EVOKE ANNOUNCES AGREEMENT WITH MALLINCKRODT TO AMEND MILESTONE PAYMENTS

BRIEF-Evoke Pharma Q4 Loss Per Share $0.02

* EVOKE PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-‍Mr Green Acquires Evoke Gaming Including Redbet​

* PURCHASE PRICE OF EUR 7 MILLION IN CASH; AN ADDITIONAL PURCHASE PRICE OF EUR 1.5 MILLION MAY BE PAYABLE IF CERTAIN CONDITIONS ARE MET

BRIEF-Evoke Pharma reports Q3 loss per share $0.34

* Evoke Pharma reports third quarter 2017 results and highlights

BRIEF-Evoke Pharma signs commercial agreement with Thermo Fisher Scientific

* Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti

BRIEF-Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti

* Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™

BRIEF-Evoke pharma completes dosing for Gimoti™comparative exposure Pharmacokinetic study

* Evoke pharma completes dosing for Gimoti™ comparative exposure Pharmacokinetic study

BRIEF-Evoke Pharma reports Q2 loss per share $0.11

* Evoke Pharma reports second quarter 2017 results and highlights

BRIEF-Evoke pharma inc initiates comparative exposure Pharmacokinetic Study for Gimoti

* Evoke Pharma Inc - initiation of its comparative exposure Pharmacokinetic trial for Gimoti

BRIEF-Evoke Pharma enters agreement with Rho to submit NDA for Gimoti

* Evoke Pharma enters agreement with Rho to submit NDA for Gimoti

BRIEF-Evoke Pharma Q1 loss per share $0.37

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial

* Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017

BRIEF-Evoke Pharma announces collaboration with Spaulding Clinical Research

* Evoke Pharma Inc- announces collaboration with Spaulding Clinical Research for Gimoti comparative exposure pharmacokinetic trial

BRIEF-Meeting with FDA confirms acceptability of Evoke's proposed trial for Gimoti NDA

* Positive type A meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA

BRIEF-Evoke Pharma Q4 loss per share $0.12

* Evoke pharma reports fourth quarter and full year 2016 results

BRIEF-Evoke Pharma announces pricing of public offering

* Evoke Pharma announces pricing of public offering of common stock

BRIEF-FDA exempts Evoke from requirement for human factor validation study

* FDA exempts Evoke from requirement for human factor validation study

BRIEF-Evoke Pharma reports Q3 loss per share of $0.29

* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up